Customized ASO therapies for ultra-rare genetic conditions carry a price tag between $1.2 and $1.4 million, a cost that forces families to navigate a market-driven system for treatments ignored by major pharmaceutical corporations. Nome, an AI-powered drug development startup, positions itself to fill this gap, offering services to patient groups often overlooked by traditional pharma due to lack of profitability.
Jacalyn Lee, founder of The DAND Alliance, experienced this neglect firsthand. Her daughter, Isla, was diagnosed with DEAF1-Associated Neurodevelopmental Disorder (DAND) at age three, a condition affecting only about 200 patients worldwide. Lee recounted receiving the diagnosis with "little else," no roadmap, minimal research, and no community support.
Lee, a communications strategist, channeled her grief into action, gathering information and connecting with researchers and other parents. She and four other mothers launched The DAND Alliance to raise money for treatment development, seeking a partner to help them prioritize spending and create a "pipeline" for progress.
The Market's Neglect
Stevie Ringel, Nome's founder, stated his company acts with "patient-level urgency" for an "underserved part of the market." His own rare genetic eye disorder, caused by a KIZ gene mutation and impacting fewer than 200 patients globally, inspired Nome's creation. There are no FDA-approved treatments for his condition.
Nome aims to function as a contract research organization (CRO) for these smaller patient groups. For The DAND Alliance, Nome delivered a 53-page report detailing next steps, from animal studies to trial design, within a timeframe and at a price point that surprised Lee.
Ringel described Nome as a "white glove service" for developing treatments, stating, "People come to us one family at a time, or as a collection of families." The company's business model involves charging customers to design clinical trials and manage the drug development process once a potential treatment is identified.
Commodification of Hope
Nome's AI platform analyzes genetic test results, identifying potential treatment options and providing a free detailed report in minutes, a process that previously took dozens of hours. The company currently produces between 80 and 100 such reports monthly.
Of approximately 5,000 cases Nome has reviewed, it has identified a programmable medicine or existing custom therapy for about 25% of known mutations. Ringel stated that Nome makes money when customers contract with them for the "actual hard work and heavy lifting," acting as a "concierge drug developer."
Ringel believes Nome can automate 60% to 80% of its drug development process within the next one to two years, up from its current 25%. He hopes that by potentially reducing the $1.2-$1.4 million cost of customized ASO therapies by 50%, a pathway for insurance coverage might emerge, comparing it to CAR-T cancer therapies that eventually gained coverage.
Capital's Influence
Ringel acknowledged Nome is in its early stages but defended its service, saying, "I don't know how you can expect these families to move this process forward without someone playing quarterback." He claimed Nome would ultimately save groups money and time, connecting "great science to the people that need it."
Nome collaborates with over 80 partners, including La Jolla Labs and Dyno Therapeutics, for drug development expertise. Jacalyn Lee expressed optimism, noting, "the slow curve of progress is now a vertical line." However, the underlying structure remains: access to life-saving treatments is contingent on private capital and market viability. The CNBC report itself was underwritten by Alexion, AstraZeneca Rare Disease, a major player in the very industry Nome purports to serve.